Henlius Reports the NMPA Acceptance of NDA for Hansizhuang (serplulimab) to Treat Esophageal Squamous Cell Carcinoma
September 25, 2023
Henlius Presents P-II Clinical Trial (HLX07-ESCC201) Results of HLX07 for the Treatment of Esophageal Squamous Cell Carcinoma at A...
June 8, 2023
Henlius Reports EMA’s Validation of MAA for Hansizhuang (serplulimab) as 1L Treatment of Extensive-Stage Small Cell Lung Cancer
March 23, 2023
Henlius Reports the US FDA Acceptance of BLA for Proposed Biosimilar Trastuzumab HLX02
February 16, 2023
Henlius' Hansizhuang (serplulimab) Receives the NMPA’s Approval as 1L Treatment of Extensive Stage Small Cell Lung Cancer
January 17, 2023
Henlius Entered into an Exclusive License Agreement with Fosun Pharma for HANSIZHUANG in the US
December 28, 2022
Back to Home
Incisive News in 3 Shots.
First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
Terms of Service
Copyright © 2023 PharmaShots - All Rights Reserved.